Shares in Puma Biotechnology jumped 40% after the FDA trod lightly around doubts about its filing for approval of breast cancer drug neratinib. But the talking points raised ahead of Wednesday’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results